pharmaceutical investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
Homerun Resources Inc. Announces Binding Distribution Agreement with Cristal Sand Group, Securing First Commercial Sales of High-Purity Industrial Silica Sand from Santa Maria Eterna
